EB Development (Consortium: NextStage AM & IK Partners) has successfully concluded its takeover bid for Eurobio Scientific, following the results of a reopened offer period. The consortium now holds 88.92% of the share capital and voting rights (including treasury shares). The offer was initiated to take the company private and provide the management team, led by Denis Fortier, with the flexibility to pursue an aggressive external growth strategy. While the bid secured a significant majority, the final participation fell just short of the 90% threshold required for a mandatory squeeze-out (retrait obligatoire). Consequently, the conditional additional price of €1.25 per share (linked to reaching the 90% mark) will not be paid to tendering shareholders. Despite remaining listed for the time being, the transaction effectively shifts Eurobio into a "private-equity-backed" development phase, allowing for deeper consolidation of the European in vitro diagnostics market.

Eurobio Scientific is a leading French player in the field of in vitro diagnostics (IVD) and "intelligent health." The company’s business model is vertically integrated, encompassing the design, development, and commercialization of specialty diagnostic kits alongside the distribution of high-end reagents and equipment for clinical laboratories and research centers. A key pillar of its value proposition is its focus on high-added-value proprietary products, reinforced by strategic acquisitions such as the 2022 purchase of GenDx, a global leader in HLA typing for transplant compatibility. Eurobio Scientific played a critical role in the post-Covid diagnostic landscape by shifting its focus toward proprietary innovation and international expansion. Operating as an "ETI" (Intermediate-Sized Enterprise), the company leverages its deep technical expertise to serve the transplantation, infectious diseases, and oncology markets, aiming to become a pan-European leader in specialized diagnostics.